Inactive Instrument

Tricida, Inc.

Equities

TCDA

US89610F1012

Biotechnology & Medical Research

Tricida, Inc. Appoints Geoffrey Parker as Chief Operating Officer

February 22, 2021 at 04:40 pm EST

On February 16, 2021, Tricida, Inc. announced that Geoffrey Parker, Chief Financial Officer and Executive Vice President has been promoted to the newly created role of Chief Operating Officer, Chief Financial Officer and Executive Vice President. Mr. Parker joined the Company in April 2017 as Chief Financial Officer and Senior Vice President and, in February 2020, he was promoted to Chief Financial Officer and Executive Vice President.

Latest news about Tricida, Inc.

Tricida, Inc. Went Out of Business	23-06-12	CI
First Motion for Exclusivity Period Extension Approved For Tricida, Inc.	23-06-01	CI
Fifth Amended Liquidation Plan Approved for Tricida, Inc.	23-05-23	CI
Fifth Amended Liquidation Plan Filed by Tricida, Inc.	23-05-22	CI
Fourth Amended Liquidation Plan Filed by Tricida, Inc.	23-05-12	CI
First Motion for Exclusivity Period Extension Filed by Tricida, Inc.	23-05-08	CI
North American Morning Briefing : China Data Helps -3-	23-04-18	DJ
North American Morning Briefing : Stock Futures -3-	23-04-11	DJ
Fourth Amended Disclosure Statement Approved for Tricida, Inc.	23-03-27	CI
Fourth Amended Disclosure Statement Filed by Tricida, Inc.	23-03-24	CI
Third Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	23-03-21	CI
Second Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	23-02-25	CI
First Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	23-02-24	CI
Motion for Asset Sale Approved for Tricida, Inc.	23-02-21	CI
Motion for Asset Sale Approved for Tricida, Inc.	23-02-21	CI
Notice of Selection of Successful Bidder Filed for Tricida, Inc.	23-02-16	CI
Notice of Selection of Successful Bidder Filed for Tricida, Inc.	23-02-16	CI
Tricida, Inc. Announces Resignation of David Bonita as Director	23-01-27	CI
Bidding Procedure Approved for Tricida, Inc.	23-01-25	CI
Tricida, Inc.(OTCPK:TCDA.Q) dropped from NASDAQ Composite Index	23-01-23	CI
Top Premarket Gainers	23-01-18	MT
Tricida, Inc.(NasdaqGS:TCDA) dropped from S&P TMI Index	23-01-18	CI
Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	23-01-17	CI
Tricida, Inc. Filed for Bankruptcy	23-01-11	CI
Motion for Asset Sale Filed by Tricida, Inc.	23-01-10	CI

Chart Tricida, Inc.

Duration

Period

More charts

Company Profile

Tricida, Inc. is a pharmaceutical company. The Company is focused on its investigational drug candidate, veverimer (TRC101). TRC101 is a non-absorbed, orally administered polymer designed to treat metabolic acidosis and slow CKD progression by binding and removing acid from the gastrointestinal (GI) tract. Its veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. Veverimer is a single, high molecular weight, crosslinked polyamine molecule. The size of veverimer prevents systemic absorption from the GI tract. The high degree of cross-linking within veverimer limits swelling and the overall volume in the GI tract, with the goal of facilitating GI tolerability. It is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+42.26%	54.04B
LONZA GROUP AG	+43.57%	41.96B
IQVIA HOLDINGS INC.	-1.16%	41.92B
CELLTRION, INC.	-7.59%	28.35B
ICON PUBLIC LIMITED COMPANY	+11.92%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-22.22%	19B
BIO-TECHNE CORPORATION	+8.04%	13B
MEDPACE HOLDINGS, INC.	+29.01%	12.28B
UNITED THERAPEUTICS CORPORATION	+25.47%	12.19B

Other Biotechnology & Medical Research